Our national breast cancer management guideline does not recommend HER2 testing as a part of standard evaluation protocol in breast cancers.29 This is consistent with the core level of resource-stratified guidelines for LMIC, which includes basic cancer medicines and basic hormonal therapies only. This evidence concerns the gene ERBB2 and cancer.